Aliases & Classifications for Pulmonary Emphysema

MalaCards integrated aliases for Pulmonary Emphysema:

Name: Pulmonary Emphysema 12 55 44 15 38 72

Classifications:



External Ids:

Disease Ontology 12 DOID:9675
ICD9CM 35 492.8
MeSH 44 D011656
ICD10 33 J43.8
UMLS 72 C0029607 C0034067

Summaries for Pulmonary Emphysema

MalaCards based summary : Pulmonary Emphysema is related to alpha-1-antitrypsin deficiency and bronchitis, and has symptoms including hemoptysis, snoring and coughing. An important gene associated with Pulmonary Emphysema is SERPINA1 (Serpin Family A Member 1), and among its related pathways/superpathways are Innate Immune System and Degradation of the extracellular matrix. The drugs Simvastatin and Sodium citrate have been mentioned in the context of this disorder. Affiliated tissues include lung, bone and testes, and related phenotypes are homeostasis/metabolism and hematopoietic system

Related Diseases for Pulmonary Emphysema

Diseases in the Pulmonary Emphysema family:

Emphysema, Hereditary Pulmonary

Diseases related to Pulmonary Emphysema via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 243)
# Related Disease Score Top Affiliating Genes
1 alpha-1-antitrypsin deficiency 32.4 SERPINA3 SERPINA1 ELN ELANE
2 bronchitis 31.8 SERPINB1 SERPINA1 ELANE
3 respiratory failure 30.9 SFTPD SERPINA1 ELANE
4 pulmonary fibrosis 30.8 TIMP1 SFTPD MMP9
5 pneumothorax 30.6 SERPINA1 MMP9 HMOX1 ELN
6 cerebral aneurysms 30.6 ELN ELANE
7 vasculitis 30.5 SERPINB1 SERPINA1 ELANE
8 diffuse pulmonary fibrosis 30.3 TIMP1 SERPINA1
9 granulomatosis with polyangiitis 30.2 SERPINB1 SERPINA1 ELANE
10 arteriosclerosis 30.2 MMP9 HMOX1 ELN
11 interstitial lung disease 30.0 TIMP1 SFTPD MMP9
12 conjunctivochalasis 30.0 TIMP2 TIMP1 MMP1
13 bronchiolitis obliterans 29.6 TIMP1 MMP9 MMP8
14 pulmonary fibrosis, idiopathic 29.5 TIMP1 SFTPD MMP9 MMP1 ELANE
15 chorioamnionitis 29.5 MMP9 MMP8 ELANE
16 bronchiectasis 29.4 SERPINA3 SERPINA1 MMP8 ELANE
17 periodontitis 28.9 TIMP1 MMP9 MMP8 MMP1
18 lung disease 28.3 SFTPD SERPINB1 SERPINA1 MMP9 MMP8 HMOX1
19 pulmonary disease, chronic obstructive 27.0 TIMP1 SFTPD SERPINB1 SERPINA3 SERPINA1 MMP9
20 berry aneurysm, cirrhosis, pulmonary emphysema, and cerebral calcification 12.4
21 autosomal recessive cutis laxa type i 12.2
22 meier-gorlin syndrome 1 11.5
23 senile ectropion 10.6 MMP9 ELN
24 elephantiasis 10.6 ELN ELANE
25 spastic entropion 10.5 MMP9 MMP1
26 autoimmune inner ear disease 10.5 TIMP1 MMP9
27 erysipelas 10.5 ELN ELANE
28 gingival hypertrophy 10.5 TIMP2 MMP9
29 internal hemorrhoid 10.5 MMP9 MMP1
30 impetigo herpetiformis 10.5 SERPINB1 ELANE
31 pulmonary hypertension 10.5
32 chromoblastomycosis 10.5 MMP9 MMP1
33 idiopathic interstitial pneumonia 10.4
34 conjunctival nevus 10.4 TIMP1 MMP9
35 cryptogenic organizing pneumonia 10.4 TIMP1 MMP9
36 adult astrocytic tumour 10.4 MMP9 MMP1
37 periodontosis 10.4 MMP9 ELANE
38 chronic actinic dermatitis 10.4 MMP9 MMP1 ELN
39 pneumothorax, primary spontaneous 10.4
40 microcystic meningioma 10.4 TIMP2 TIMP1
41 fibrosis of extraocular muscles, congenital, 1 10.3
42 liver cirrhosis 10.3
43 silicosis 10.3
44 anthracosis 10.3
45 peptic ulcer disease 10.3
46 lipodermatosclerosis 10.3 TIMP2 MMP1
47 central nervous system tuberculosis 10.3 TIMP1 MMP9 ELANE
48 gastrointestinal ulceration, recurrent, with dysfunctional platelets 10.3
49 kawasaki disease 10.3 TIMP1 MMP9 ELANE
50 asthma 10.3

Comorbidity relations with Pulmonary Emphysema via Phenotypic Disease Network (PDN):


Heart Disease

Graphical network of the top 20 diseases related to Pulmonary Emphysema:



Diseases related to Pulmonary Emphysema

Symptoms & Phenotypes for Pulmonary Emphysema

UMLS symptoms related to Pulmonary Emphysema:


hemoptysis, snoring, coughing

MGI Mouse Phenotypes related to Pulmonary Emphysema:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 10 ELANE HMOX1 MMP1 MMP12 MMP8 MMP9
2 hematopoietic system MP:0005397 9.92 ELANE HMOX1 MMP12 MMP9 SERPINB1 SFTPD
3 immune system MP:0005387 9.85 ELANE HMOX1 MMP1 MMP12 MMP8 MMP9
4 neoplasm MP:0002006 9.35 ELANE MMP1 MMP8 MMP9 TIMP1
5 respiratory system MP:0005388 9.17 HMOX1 MMP12 MMP9 SERPINB1 SESN2 SFTPD

Drugs & Therapeutics for Pulmonary Emphysema

Drugs for Pulmonary Emphysema (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 124)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Simvastatin Approved Phase 4 79902-63-9 54454
2
Sodium citrate Approved, Investigational Phase 4 68-04-2
3
Losartan Approved Phase 4 114798-26-4 3961
4
Angiotensin II Approved, Investigational Phase 4 11128-99-7, 68521-88-0, 4474-91-3 172198
5
Lamivudine Approved, Investigational Phase 4 134678-17-4 60825
6
Emtricitabine Approved, Investigational Phase 4 143491-57-0 60877
7
Dolutegravir Approved Phase 4 1051375-16-6 54726191
8
Citric acid Approved, Nutraceutical, Vet_approved Phase 4 77-92-9 311
9
Lactitol Investigational Phase 4 585-86-4, 585-88-6 493591
10
Tenofovir Experimental, Investigational Phase 4 147127-20-6 464205
11
Salmeterol xinafoate Phase 4 94749-08-3 56801
12 Anesthetics Phase 4
13 Lipid Regulating Agents Phase 4
14 Hydroxymethylglutaryl-CoA Reductase Inhibitors Phase 4
15 Hypolipidemic Agents Phase 4
16 Anticholesteremic Agents Phase 4
17 Antimetabolites Phase 4
18 Parasympatholytics Phase 4
19 Cholinergic Agents Phase 4
20 Tiotropium Bromide Phase 4 136310-93-5
21 Cholinergic Antagonists Phase 4
22 Bromides Phase 4
23 Gastrointestinal Agents Phase 4
24 Cathartics Phase 4
25 Laxatives Phase 4
26 Sildenafil Citrate Phase 4 171599-83-0
27 Citrate Phase 4
28 Phosphodiesterase Inhibitors Phase 4
29 Phosphodiesterase 5 Inhibitors Phase 4
30 Vasodilator Agents Phase 4
31 Angiotensinogen Phase 4
32 Angiotensin II Type 1 Receptor Blockers Phase 4
33 Giapreza Phase 4
34 Angiotensin Receptor Antagonists Phase 4
35 Anti-Arrhythmia Agents Phase 4
36 Antihypertensive Agents Phase 4
37 Anti-Infective Agents Phase 4
38 Integrase Inhibitors Phase 4
39 Nucleic Acid Synthesis Inhibitors Phase 4
40 HIV Integrase Inhibitors Phase 4
41 Reverse Transcriptase Inhibitors Phase 4
42 Anti-HIV Agents Phase 4
43 Anti-Retroviral Agents Phase 4
44 Antiviral Agents Phase 4
45
Budesonide Approved Phase 3 51333-22-3 63006 5281004
46 Budesonide, Formoterol Fumarate Drug Combination Phase 3
47 Hormone Antagonists Phase 3
48 Sympathomimetics Phase 3
49 Hormones Phase 3
50 glucocorticoids Phase 3

Interventional clinical trials:

(show top 50) (show all 188)
# Name Status NCT ID Phase Drugs
1 Utility of the AeriSeal System in Patients With Advanced Upper Lobe Predominant Emphysema and Collateral Ventilation Assessed by the Chartis System Unknown status NCT01460108 Phase 4
2 Doxycycline and Airway Inflammation in COPD: A Randomised Placebo Controlled Trial Studying the Effects of Doxycycline on Airway Inflammation in Patients With Moderate and Severe Stable COPD. Unknown status NCT00857038 Phase 4 Doxycycline;Placebo
3 A Multi-Center, Prospective, Clinical Trial Designed to Study the Efficacy of One-Way Valve Implantation Based on a New Treatment Algorithm in Patients With Heterogeneous Emphysema Unknown status NCT00730301 Phase 4
4 The Effects of Simvastatin in Patients With Chronic Obstructive Pulmonary Disease Unknown status NCT00680641 Phase 4 Simvastatin;Placebo
5 Inspiratory Capacity and HRCT Comparison of Nebulized Arformoterol (Brovana) vs. Dry-powder Inhaler Salmeterol (Serevent) Unknown status NCT01361984 Phase 4 Nebulized arformoterol;Salmeterol
6 Pilot Study for Perfusion Heterogeneity: a Mechanistic Image-Based Emphysema Phenotype Completed NCT03733470 Phase 4 Hypoxia Administration study group;Hyperoxia Administration study group;Sildenafil study group
7 Efficacy of Losartan in Preventing Progression of COPD Completed NCT00720226 Phase 4 Losartan;Placebo
8 An Open-label, Non-controlled, Multicenter, Multinational Study to Evaluate the Efficacy and Safety of Zemaira® Administration in Chronic Augmentation and Maintenance Therapy in Subjects With Emphysema Due to alpha1-proteinase Inhibitor Deficiency Who Completed Clinical Study CE1226_4001 Completed NCT00670007 Phase 4
9 A Randomized, Placebo-Controlled, Double-Blind, Multicenter Phase III/IV Study to Compare the Efficacy and Safety of 60mg/kg Body Weight of Zemaira® Weekly I.V. Administration With Placebo Weekly I.V. Administration in Chronic Augmentation and Maintenance Therapy in Subjects With Emphysema Due to Alpha1-Proteinase Inhibitor Deficiency Completed NCT00261833 Phase 4
10 A Two-Week, Randomized, Modified-Blind, Double-Dummy, Parallel-Group Efficacy and Safety Study of Arformoterol Tartrate Inhalation Solution Twice-Daily, Tiotropium Once-Daily, and Arformoterol Tartrate Inhalation Solution Twice-Daily and Tiotropium Once Daily in Subjects With Chronic Obstructive Pulmonary Disease Completed NCT00424528 Phase 4 Arformoterol Tartrate Inhalation Solution;Tiotropium;Arformoterol and Tiotropium;Placebo
11 Randomised Cross-over Study to Compare the Effect of Formoterol Plus Tiotropium Versus Formoterol Monotherapy on Breathlessness, Dynamic Hyperinflation and Exercise Tolerance in Moderate-to-severe Stable COPD Patients Completed NCT00680056 Phase 4 Formoterol plus Placebo (Tiotropium);Formoterol plus Tiotropium
12 Acute Effect of Pulmonary Desufflation on Cardiac Performance in COPD Patients in Stable Conditions. Pilot Study Completed NCT01996124 Phase 4 Indacaterol Fumarate;Placebo
13 Losartan Effects on Emphysema Progression Recruiting NCT02696564 Phase 4 Losartan;Placebo
14 Smoking Cessation and Functional CT Assessment of Pulmonary Arterial Dysfunction in Smoking Associated Emphysema Recruiting NCT03382106 Phase 4 Sildenafil 20 MG;Placebo Oral Tablet
15 Functional CT Assessment of Pulmonary Arterial Dysfunction in Smoking Associated Emphysema Recruiting NCT02682147 Phase 4 Hypoxia administration study group;Hyperoxia administration study group;Sildenafil
16 Evaluating Inflammatory and Immunological Changes of HIV-positive Patients Switching to DTG Dual Regimen Compared to Those Switching to a Triple Drugs Regimen (B/F/TAF) Not yet recruiting NCT04054089 Phase 4 Bictegravir 50 MG / Emtricitabine 200 MG / Tenofovir Alafenamide 25 MG [Biktarvy];dolutegravir 50 mg / lamivudine 300 mg
17 Collateral Ventilation Effects on Response to AeriSeal System Treatment in Upper Lobe Predominant Emphysema Terminated NCT01520740 Phase 4
18 Perforomist Versus Foradil Evaluated by Inspiratory Capacity and HRCT Withdrawn NCT00633776 Phase 4 formoterol fumarate
19 Unilateral vs. Bilateral IBV Placement Unknown status NCT00995852 Phase 2, Phase 3
20 Sequential Endoscopic Lung Volume Reduction in Patients With Heterogeneous Lung Emphysema Unknown status NCT00613860 Phase 3
21 Effect of Symbicort on Sleep Quality in Patients With Emphysema Unknown status NCT01602523 Phase 3 Budesonide/formoterol;Placebo
22 Endoscopic Lung Volume Reduction by Implantation of Endobronchial Valves (EBV) vs. Intrabronchial Valves (IBV) in Patients With Severe Heterogeneous Emphysema Unknown status NCT01457833 Phase 2, Phase 3
23 Endoscopic Lung Volume Reduction in Patients With Advanced Emphysema Due to alpha1 Antitrypsin Deficiency Unknown status NCT01357460 Phase 2, Phase 3
24 Bronchoscopic Volume Reduction With Valve Implants After Analysis of Interlobar Fissure Integrity and Measurement of Collateral Ventilation in Patients With Severe, Heterogeneous Emphysema Unknown status NCT01902732 Phase 2, Phase 3
25 A Randomized, Double-blind Study to Evaluate the Safety and Effectiveness of the Exhale® Drug-Eluting Stent in Homogeneous Emphysema Subjects With Severe Hyperinflation Unknown status NCT00391612 Phase 3
26 Clinical Evaluation of GW815SF for Chronic Obstructive Pulmonary Disease (Chronic Bronchitis, Emphysema)" A Long-term Treatment Study of GW815SF50/500µg in Chronic Obstructive Pulmonary Disease - Completed NCT00269087 Phase 3 fluticasone propionate/salmeterol combination DISKUS
27 A Phase II/III, Double-Blind, Randomized, Placebo-Controlled, Multicenter, International Study Evaluating the Safety and Efficacy of Inhaled, Human, Alpha-1 Antitrypsin (AAT) in Alpha-1 Antitrypsin Deficient Patients With Emphysema Completed NCT01217671 Phase 2, Phase 3
28 Evaluation of Physiologic Parameters to Study the Mechanism of Action of the PneumRx, Inc. Lung Volume Reduction Coil (LVRC) in Subjects With Homogeneous Emphysema Completed NCT01421082 Phase 2, Phase 3
29 Multi-center, Open-label Trial to Evaluate the Safety and Tolerability of Alpha-1 MP in Subjects With Alpha-1-antitrypsin (AAT) Deficiency Completed NCT00301366 Phase 3 alpha-1 proteinase inhibitor (human)
30 A Study of the AeriSeal® System Administered at 3 to 4 Sites During a Single Treatment Session for Lung Volume Reduction in Patients With Advanced Emphysema Completed NCT01181466 Phase 2, Phase 3
31 The Effect and Mechanism of Bronchoscopic Lung Volume Reduction by Endobronchial Valve in Korean Emphysema Patients Completed NCT01869205 Phase 3
32 Randomized Double-Blind Comparison of an Alpha-1 Proteinase Inhibitor (Kamada API) With a Currently Marketed API Product in Individuals With Alpha-1 Antitrypsin Deficiency Completed NCT00460096 Phase 2, Phase 3 Kamada-API
33 Comparative Study of Bronchoscopic Lung Volume Reduction to Evaluate Relative Efficacy in Patients With Non-Upper Lobe Emphysema Completed NCT00825578 Phase 3
34 Multi-center, Randomized, Double-blind, Crossover Trial to Evaluate the Pharmacokinetic Comparability of Alpha-1 MP to Prolastin in Subjects With Alpha1-antitrypsin Deficiency. Completed NCT00295061 Phase 3 Alpha-1 MP;alpha-1 proteinase inhibitor (human)
35 Multicenter, Double-Blind, Double-Dummy, Randomized, Active-Controlled, Parallel Group Long-Term Safety Study of 15 μg and 25 μg Arformoterol Tartrate Inhalation Solution BID in Subjects With Chronic Obstructive Pulmonary Disease Completed NCT00250679 Phase 3 Arformoterol tartrate inhalation solution;Arformoterol 25 ųg BID;Formoterol 12 ųg BID;Placebo
36 Endobronchial Valve for Emphysema Palliation Trial (VENT) Completed NCT00129584 Phase 3
37 A Prospective Feasibility Study to Evaluate the Safety and Performance of the Exhale(R) Drug-Eluting Stent System in Patients With Emphysema Completed NCT00207337 Phase 2, Phase 3
38 National Emphysema Treatment Trial (NETT) Completed NCT00000606 Phase 3
39 A Randomized, Double-Blind, Placebo Controlled Study to Assess the Efficacy and Safety of Two Dose Regimens (60 mg/kg and 120 mg/kg) of Weekly Intravenous Alpha1 Proteinase Inhibitor (Human) in Subjects With Pulmonary Emphysema Due to Alpha1 Antitrypsin Deficiency Recruiting NCT01983241 Phase 3
40 Cost-effectiveness of Lung Volume Reduction Coil Treatment in Emphysema. Active, not recruiting NCT01822795 Phase 3
41 An Open-Label, Multicenter Study to Evaluate the Long-term Safety of Weekly Intravenous Alpha1-Proteinase Inhibitor (Human), Modified Process 60 mg/kg in Subjects With Pulmonary Emphysema Due to Alpha1-Antitrypsin Deficiency Enrolling by invitation NCT02796937 Phase 3
42 Bone Marrow-Derived Mesenchymal Stromal Cell Therapy Associated With Unidirectional Endobronchial Valve in Patients With Severe Pulmonary Emphysema: A Randomized Clinical Trial Not yet recruiting NCT04018729 Phase 2, Phase 3
43 The Effect of Nutritional Support on Gait Speed Following Hospitalisation for Acute Exacerbation of COPD Terminated NCT02261350 Phase 3
44 Study of the AeriSeal System for HyPerInflation Reduction in Emphysema (ASPIRE) Terminated NCT01449292 Phase 3
45 A Continuation Study of the AeriSeal® System Administered at 3 to 4 Sites During a Single Treatment Session for Lung Volume Reduction in Patients With Advanced Emphysema Terminated NCT01320566 Phase 2, Phase 3
46 Endobronchial Valve for Emphysema PalliatioN Trial (VENT) Cost-effectiveness Sub-Study Terminated NCT00137956 Phase 3
47 Study of the AeriSeal System Treatment in Patients With Advanced Non-Upper Lobe Predominant Heterogeneous Emphysema Withdrawn NCT01908933 Phase 3
48 Phase 3 Study of the Biologic Lung Volume Reduction (BLVR) System in Patients With Advanced Upper Lobe Predominant Emphysema Withdrawn NCT00716053 Phase 3 BLVR
49 A Feasibility and Safety Study of Bronchoscopic Intrabullous Autologous Blood Instillation for the Treatment of Severe Bullous Emphysema (BIABI Study) Unknown status NCT01727037 Phase 2
50 Cell Therapy in Advanced Chronic Obstructive Pulmonary Disease Patients Unknown status NCT02412332 Phase 1, Phase 2

Search NIH Clinical Center for Pulmonary Emphysema

Inferred drug relations via UMLS 72 / NDF-RT 51 :


Acetylcysteine
Alpha-1-proteinase inhibitor
Aminophylline
aminophylline dihydrate
AMINOPHYLLINE PWDR
Fluticasone propionate
iodinated glycerol
Ipratropium
Ipratropium Bromide
Orciprenaline
oxtriphylline
Theophylline
Theophylline anhydrous
Theophylline calcium salicylate
Theophylline Sodium Glycinate

Cell-based therapeutics:


LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database
Read about Pulmonary Emphysema cell therapies at LifeMap Discovery.

Cochrane evidence based reviews: pulmonary emphysema

Genetic Tests for Pulmonary Emphysema

Anatomical Context for Pulmonary Emphysema

MalaCards organs/tissues related to Pulmonary Emphysema:

41
Lung, Bone, Testes, Heart, Neutrophil, Liver, Bone Marrow

Publications for Pulmonary Emphysema

Articles related to Pulmonary Emphysema:

(show top 50) (show all 3853)
# Title Authors PMID Year
1
Extensive Analysis of Elastase-Induced Pulmonary Emphysema in Rats: ALP in the Lung, a New Biomarker for Disease Progression? 9 38
20216950 2010
2
[Update: Alpha-1-antitrypsin deficiency. Summary of a scientific symposium at the conference of the Swiss Pneumologic Society on April 16th, 2009]. 9 38
19941265 2009
3
alpha1-Antitrypsin deficiency: best clinical practice. 9 38
19783716 2009
4
Selective MMP-12 inhibitors: WO-2008057254. 9 38
19456279 2009
5
Neutrophil elastase cleaves VEGF to generate a VEGF fragment with altered activity. 9 38
19136576 2009
6
A recombinant fragment of human surfactant protein D lacking the short collagen-like stalk fails to correct morphological alterations in lungs of SP-D deficient mice. 9 38
19177340 2009
7
Dysregulation of elastin expression by fibroblasts in pulmonary emphysema: role of cellular retinoic acid binding protein 2. 9 38
18621984 2008
8
alpha1-antitrypsin (A1AT) deficiency presenting with IgA nephropathy and nephrotic syndrome: is renal involvement caused by A1AT deposition? 9 38
18793532 2008
9
Alpha-1-antitrypsin deficiency (Siiyama) as indication for lung transplantation: proper timing for surgical intervention. 9 38
18577911 2008
10
Age of SERPINA1 gene PI Z mutation: Swedish and Latvian population analysis. 9 38
18294358 2008
11
Matrix metalloproteinase expression by human alveolar macrophages in relation to emphysema. 9 38
18259971 2008
12
[Polymorphism in promoter regions of matrix metalloproteinases (MMP1, MMP9, and MMP12) in chronic obstructive pulmonary disease patients]. 9 38
18619044 2008
13
Premature aging in klotho mutant mice: cause or consequence? 9 38
17353153 2007
14
Rapid and inexpensive detection of alpha1-antitrypsin deficiency-related alleles S and Z by a real-time polymerase chain reaction suitable for a large-scale population-based screening. 9 38
17251342 2007
15
Study of human lung elastin degradation by different elastases using high-performance liquid chromatography/mass spectrometry. 9 38
16962555 2006
16
alpha-1 antitrypsin inhibits caspase-3 activity, preventing lung endothelial cell apoptosis. 9 38
17003475 2006
17
Matrix metalloproteinase-9 promoter polymorphism associated with upper lung dominant emphysema. 9 38
16126934 2005
18
Autosomal dominant cutis laxa with severe lung disease: synthesis and matrix deposition of mutant tropoelastin. 9 38
15955094 2005
19
Prevalence of alpha1-antitrypsin phenotypes in patients with IgA nephropathy. 9 38
15630900 2004
20
Extracellular regulated kinase/mitogen activated protein kinase is up-regulated in pulmonary emphysema and mediates matrix metalloproteinase-1 induction by cigarette smoke. 9 38
14764579 2004
21
Retinoic acid fails to reverse emphysema in adult mouse models. 9 38
14985558 2004
22
Imbalance of matrix metalloproteinase-9 and tissue inhibitor of matrix metalloproteinase-1 is associated with pulmonary emphysema in Klotho mice. 9 38
15864012 2004
23
Can exogenously administered hyaluronan improve respiratory function in patients with pulmonary emphysema? 9 38
14718453 2004
24
A recombinant fragment of human surfactant protein D reduces alveolar macrophage apoptosis and pro-inflammatory cytokines in mice developing pulmonary emphysema. 9 38
15033705 2003
25
Microsatellite polymorphism in heme oxygenase-1 gene promoter is associated with susceptibility to oxidant-induced apoptosis in lymphoblastoid cell lines. 9 38
12730098 2003
26
Emphysema due to alpha-antitrypsin deficiency: familial study of the YBARCELONA variant. 9 38
12853554 2003
27
A novel oral neutrophil elastase inhibitor (ONO-6818) inhibits human neutrophil elastase-induced emphysema in rats. 9 38
12186827 2002
28
Influence of deficient alpha1-anti-trypsin phenotypes on clinical characteristics and severity of asthma in adults. 9 38
11905553 2002
29
Genetic polymorphisms of matrix metalloproteinases: functional importance in the development of chronic obstructive pulmonary disease? 9 38
12383023 2002
30
Genetic polymorphism in matrix metalloproteinase-9 and pulmonary emphysema. 9 38
11708786 2001
31
Matrix metalloproteinases and TIMPs: properties and implications for the treatment of chronic obstructive pulmonary disease. 9 38
11199097 2001
32
[The elastases]. 9 38
11723830 2001
33
Kinetics of equine neutrophil elastase release and superoxide anion generation following secretagogue activation: a potential mechanism for antiproteinase inactivation. 9 38
10628671 1999
34
A randomized clinical trial of alpha(1)-antitrypsin augmentation therapy. 9 38
10556107 1999
35
[Elastase anti-elastase imbalance in the pathogenesis of COPD]. 9 38
10497394 1999
36
Neutrophil granule proteins in bronchoalveolar lavage fluid from subjects with subclinical emphysema. 9 38
10351949 1999
37
Inhibition of elastase-induced acute inflammation and pulmonary emphysema in hamsters by a novel neutrophil elastase inhibitor FR901277. 9 38
10219659 1999
38
A national program for detection of alpha 1-antitrypsin deficiency in Italy. Gruppo I.D.A. 9 38
10464873 1999
39
Environmental correlates of impaired lung function in non-smokers with severe alpha 1-antitrypsin deficiency (PiZZ). 9 38
10193391 1998
40
Relations between cardiopulmonary exercise testing and quantitative high-resolution computed tomography associated in patients with alpha-1-antitrypsin deficiency. 9 38
9810033 1998
41
Matrix metalloproteinase-mediated extracellular matrix protein degradation in human pulmonary emphysema. 9 38
9759652 1998
42
Biochemical and pharmacological characterization of FR134043, a novel elastase inhibitor. 9 38
9592030 1998
43
Relationship of serum elastin peptide level to single breath transfer factor for carbon monoxide in French coal miners. 9 38
9516897 1997
44
Biochemical and pharmacological characterization of FK706, a novel elastase inhibitor. 9 38
9389382 1997
45
[Molecular characterization of two variants of alpha-1-antitrypsin deficiency: PI Mpalermo and PI Plovel]. 9 38
9441182 1997
46
[Metalloproteinases in the extracellular matrix: structure and activity]. 9 38
9082500 1997
47
The nitrite/elastin reaction: implications for in vivo degenerative effects. 9 38
9512892 1997
48
[Neutrophil elastase and elastin-derived peptides in BAL fluid and emphysematous changes on CT scans]. 9 38
9216188 1996
49
[Study of the frequency of different phenotypes of alpha-1-antitrypsin in a population of Barcelona]. 9 38
8755448 1996
50
[Structure and expression of the human neutrophil elastase gene--regulatory mechanism and its relevance to the respiratory diseases]. 9 38
8838087 1996

Variations for Pulmonary Emphysema

Expression for Pulmonary Emphysema

LifeMap Discovery
Genes differentially expressed in tissues of Pulmonary Emphysema patients vs. healthy controls: 35
# Gene Description Tissue Up/Dn Fold Change (log2) P value
1 S100A12 S100 calcium binding protein A12 Lung - 3.38 0.026
2 SERPIND1 serpin peptidase inhibitor, clade D (heparin cofactor), member 1 Lung + 3.23 0.020
3 HLA-DOA major histocompatibility complex, class II, DO alpha Lung + 3.20 0.002
Search GEO for disease gene expression data for Pulmonary Emphysema.

Pathways for Pulmonary Emphysema

Pathways related to Pulmonary Emphysema according to GeneCards Suite gene sharing:

(show all 15)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.79 TIMP2 TIMP1 SERPINB1 SERPINA3 SERPINA1 MMP9
2
Show member pathways
12.41 TIMP2 TIMP1 MMP9 MMP8 MMP12 MMP1
3
Show member pathways
12.01 MMP9 MMP8 MMP12 MMP1 ELN
4 11.94 MMP9 MMP12 MMP1
5 11.81 TIMP1 MMP9 MMP1 HMOX1
6 11.62 TIMP2 TIMP1 MMP9 HMOX1
7 11.52 TIMP1 SERPINA1 MMP9 HMOX1 ELN
8 11.44 TIMP2 TIMP1 MMP9 MMP12 MMP1
9 11.18 MMP9 MMP1 HMOX1
10
Show member pathways
11.16 TIMP2 TIMP1 MMP9 MMP8 MMP12 MMP1
11 11.01 TIMP2 TIMP1 MMP9
12 10.94 TIMP2 MMP9 MMP1 ELN ELANE
13 10.92 TIMP2 MMP9
14 10.86 TIMP1 SERPINA3 MMP1
15 10.75 MMP9 MMP1

GO Terms for Pulmonary Emphysema

Cellular components related to Pulmonary Emphysema according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular space GO:0005615 9.9 TIMP2 TIMP1 SFTPD SERPINB1 SERPINA3 SERPINA1
2 extracellular matrix GO:0031012 9.8 TIMP2 TIMP1 MMP9 MMP8 MMP12 MMP1
3 extracellular region GO:0005576 9.73 TIMP2 TIMP1 SFTPD SERPINB1 SERPINA3 SERPINA1
4 ficolin-1-rich granule lumen GO:1904813 9.61 TIMP2 SERPINA1 MMP9
5 platelet alpha granule lumen GO:0031093 9.58 TIMP1 SERPINA3 SERPINA1
6 specific granule lumen GO:0035580 9.54 TIMP2 MMP8 ELANE
7 tertiary granule lumen GO:1904724 9.5 TIMP2 MMP9 MMP8
8 collagen-containing extracellular matrix GO:0062023 9.23 TIMP2 SERPINB1 SERPINA3 SERPINA1 MMP9 MMP8

Biological processes related to Pulmonary Emphysema according to GeneCards Suite gene sharing:

(show all 16)
# Name GO ID Score Top Affiliating Genes
1 proteolysis GO:0006508 9.89 MMP9 MMP8 MMP12 MMP1 ELANE
2 cytokine-mediated signaling pathway GO:0019221 9.78 TIMP1 MMP9 MMP1 HMOX1
3 cellular protein metabolic process GO:0044267 9.73 TIMP1 SFTPD SERPINA1 MMP1
4 negative regulation of endopeptidase activity GO:0010951 9.72 TIMP2 TIMP1 SERPINB1 SERPINA3 SERPINA1
5 platelet degranulation GO:0002576 9.69 TIMP1 SERPINA3 SERPINA1
6 negative regulation of peptidase activity GO:0010466 9.65 TIMP2 TIMP1 SERPINB1 SERPINA3 SERPINA1
7 leukocyte migration GO:0050900 9.56 MMP1 ELANE
8 positive regulation of macroautophagy GO:0016239 9.55 SESN2 HMOX1
9 positive regulation of DNA binding GO:0043388 9.54 MMP9 MMP8
10 endodermal cell differentiation GO:0035987 9.52 MMP9 MMP8
11 neutrophil degranulation GO:0043312 9.5 TIMP2 SERPINB1 SERPINA3 SERPINA1 MMP9 MMP8
12 negative regulation of membrane protein ectodomain proteolysis GO:0051045 9.46 TIMP2 TIMP1
13 collagen catabolic process GO:0030574 9.46 MMP9 MMP8 MMP12 MMP1
14 regulation of neuroinflammatory response GO:0150077 9.4 MMP9 MMP8
15 negative regulation of metallopeptidase activity GO:1905049 9.37 TIMP2 TIMP1
16 extracellular matrix disassembly GO:0022617 9.17 TIMP2 TIMP1 MMP9 MMP8 MMP12 MMP1

Molecular functions related to Pulmonary Emphysema according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 zinc ion binding GO:0008270 9.88 TIMP2 TIMP1 MMP9 MMP8 MMP12 MMP1
2 peptidase activity GO:0008233 9.83 MMP9 MMP8 MMP12 MMP1 ELANE
3 metallopeptidase activity GO:0008237 9.67 MMP9 MMP8 MMP12 MMP1
4 serine-type endopeptidase inhibitor activity GO:0004867 9.63 SERPINB1 SERPINA3 SERPINA1
5 metalloendopeptidase activity GO:0004222 9.62 MMP9 MMP8 MMP12 MMP1
6 protease binding GO:0002020 9.56 TIMP2 TIMP1 SERPINA1 ELANE
7 metalloendopeptidase inhibitor activity GO:0008191 9.48 TIMP2 TIMP1
8 serine-type endopeptidase activity GO:0004252 9.46 MMP9 MMP8 MMP1 ELANE
9 peptidase inhibitor activity GO:0030414 9.35 TIMP2 TIMP1 SERPINB1 SERPINA3 SERPINA1
10 endopeptidase activity GO:0004175 9.02 MMP9 MMP8 MMP12 MMP1 ELANE

Sources for Pulmonary Emphysema

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 TGDB
71 Tocris
72 UMLS
73 UMLS via Orphanet
Content
Loading form....